421 results about "Cannabinoid" patented technology

Various aspects of this disclosure relate to methods to lower the activation energy of the cannabinoid decarboxylation reaction by performing the decarboxylation reaction in the gas phase.

The present invention relates to a cannabinoid containing oral solution. Preferably the oral solution comprises a cannabinoid, a lipid solvent, a sweetener and ethanol, characterised in that the sweetener is an ultrahigh potency sweetener.

Provided are methods of preparing cannabinoids and cannabinoid derivatives and compositions containing the cannabinoids and derivatives.

The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The present invention relates to a composition of cannabinoid compounds having a structural formula I as defined herein. The invention also relates to compositions comprising these compounds, to processes for preparing these compounds, to intermediates useful for preparing these compounds and to the use of these compounds as medicaments, in particular for the treatment of conditions associated with epileptic seizures, such as epilepsy.

The present invention relates to compositions comprising phospholipids for delivery of bioactive compounds such as ethyl esters, fish oil concentrates, cannabinoids, CoQ10 and curcumin under conditions such the bioavailability of the bioactive compounds is enhanced.

The disclosure provides a nanoemulsion including an oil phase containing at least one cannabinoid and a water phase; wherein at least one of the oil phase and the water phase includes one or more emulsifying agents; and wherein the zeta potential of the nanoemulsion is less than about −10 mV. Further provided are processes for preparing such nanoemulsions.

The present invention relates to a group of cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof. The cannabinoid derivatives of the invention are analogues of cannabidiol (CBD). CBD is a non-psychoactive cannabinoid which has been used to treat various diseases and disorders. While such treatments hold promise, there remains a need in the art for more effective treatments and this has been brought about by way of the cannabinoid derivatives of the invention

Bioavailable compositions are provided. The bioavailable compositions comprise emulsions. The emulsions comprise: water; a cannabinoid; a carrier; an emulsifier; and a cyclodextrin. The bioavailable compositions may further comprise an excipient and / or a terpene. The bioavailable compositions may comprise thin films. The thin films may be mucosally dissolvable films.

This disclosure presents describes methods for the chemical glycosylation and glucuronidation of cannabinoids. These methods use readily available glycosyl and glucuronyl donors and offer a convenient and versatile approach to access a diverse range of cannabinoid glycosides and glucuronides. Selected compounds have been evaluated for their physicochemical properties and in vitro stability to understand the structure-property relationship and identify their potential applications. The possible uses of these compounds could span various fields, including medicine, consumer goods, and nutrition supplements.

The present invention provides cannabinoid derivatives, pharmaceutical compositions comprising same, and methods of use thereof as medicaments.

Pharmaceutical composition comprising one or more cannabinoids (e.g., cannabidiol; 15-25 % w / w), one or more cyclodextrins or cyclodextrin derivatives (e.g., α-cyclodextrin (alpha-CD) or hydropropyl-β

The disclosed formulations include Diclofenac Sodium Salt and at least one cannabinoid. Other formulations include other anti-inflammatory drugs such as methotrexate and prednisone, for example. In addition, methods of using formulations to treat diseases or disorders such as arthritis, pain, inflammation and fever are disclosed.

Provided are methods of preparing cannabinoids and cannabinoid derivatives and compositions containing the cannabinoids and derivatives.

The present invention relates to a method for subjecting a subject to an augmented reality (AR) or virtual reality (VR) experience. The method may comprise administering to the subject a composition comprising a cannabinoid compound. The method may comprise, subsequent to the administration of the composition comprising the cannabinoid compound, using an AR or VR device to subject the subject to an AR or VR experience. The method may comprise detecting a response of the subject to the AR or VR experience and the composition comprising the cannabinoid compound.

A method for cooking savory food with a cannabinoid containing mixture. The method comprising the general steps of making a cannabinoid containing mixture and mixing the cannabinoid containing mixture with a savory food item, such as a brisket. In one exemplary embodiment, the cannabinoid containing mixture comprises brown sugar, garlic powder, onion powder, salt, black pepper, cajun seasoning, peppercorn pepper, white sugar, and a therapeutic amount of CBD or THC. If desired, a spicey component, such as habanero peppers, may be added to the cannabinoid containing mixture to add heat.

A Cannabis processing system comprises a grinding apparatus and a cell disruption apparatus. The grinding apparatus is configured to grind wet Cannabis cuttings to from a ground, wet Cannabis material comprising wet Cannabis particles having an average particle size within a range of from about 1 mm to about 3 mm. The cell disruption apparatus is downstream of the grinding apparatus and is configured to disrupt cell walls of plant cells of the wet Cannabis particles through one or more of flash freezing, a cellulose solvent, applied negative pressure, and vacuum distillation to facilitate removal of one or more cannabinoids within the plant cells of the wet Cannabis particles. Methods of processing Cannabis are also described.

The present disclosure provides pharmaceutical compositions comprising a cannabinoid, and dosage forms comprising same, for oral delivery, such as sublingual or buccal delivery. The compositions of the present disclosure are substantially homogeneous and remain stable and monophasic upon storage. Also provided are methods of using the compositions for pain management and to treat various diseases and conditions, including dementia, sleep disorders, movement disorders, mental disorders, and multiple sclerosis.

The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a Cannabinoids-Related Disorder. More particularly, the invention relates to a compound of Formula (I)for its use in the treatment of a Cannabinoids-Related Disorder. Indeed, the compound of the invention is in vivo very potent in inhibiting the effects of THC, and is able to inhibit both unconditioned and conditioned effects of THC including THC self-administration and reinstatement in THC seeking in non-human primates.

Provided herein are methods of treating cannabinoid-induced toxicity. Further provided herein are injectable compositions for treating acute cannabinoid overdose, poisoning, or acute cannabinoid-induced CNS depression. Further provided herein are methods of treating cannabinoid-induced toxicity in pediatric patients.

The present disclosure concerns methods for reducing nicotine dependency, i.e. by reducing tobacco smoking and promoting tobacco smoking secession; and by reducing marijuana dependency, i.e. by reducing marijuana smoking and promoting marijuana smoking cessation. More particularly the present disclosure concerns formulations of cannabinoids for use in reducing nicotine and marijuana dependency and promoting tobacco and marijuana smoking secession.

The invention discloses a biosynthesis method and application of cannabinoid compounds. The specific method comprises the following steps: constructing a non-reductive polyketide synthase (NRPKS) AtnG from a fungus Arthrinum sp.NF2194, an isopentenyl transferase NphBV49W / Y288P from an actinomycetes Streptomyces sp.CL190, a cyclase Svz9 from an actinomycetes Streptoviensis NA431, a GPP synthase AgGPPS from a plant Abis grandis and a terpene synthesis enhancement path MEV into a heterologous expression vector, and sequentially introducing the heterologous expression vector into escherichia coli, so as to successfully realize the production of the cannabinoid compounds OA, CBGA and CBCA. The cannabinoid compound disclosed by the invention has important medical and industrial values.

Aspects of disclosure relate to a composition and methodology for treating menopause symptoms utilizing a cannabinoid-based nanoplatform composition. The composition includes phytocannabinoids like CBD, CBG, and CBN, alongside isoflavones and polyphenols, all integrated into nanoplatform designed for enhanced bioavailability and controlled release. The formulation is designed to alleviate key menopause-related issues, including vasomotor symptoms (VMS), genitourinary syndrome of menopause (GSM), bone loss, mood disturbances, and sleep disorders, while addressing cardiovascular disease (CVD) risks. The composition combines cannabinoids, such as CBD, with isoflavones and polyphenols, and is incorporated into nanoplatforms for enhanced delivery and efficacy. Additionally, the disclosure includes a kit comprising oral capsules, intravaginal ovules, and instructions for use. The capsules contain a blend of cannabinoids, flavonoids, and polyphenols, while the ovules are composed of CBD and cocoa butter. The kit provides a comprehensive solution for managing menopause symptoms and mitigating cardiovascular risks.

To provide novel therapeutic compositions for systemic administration (e.g., oral administration) and long-term release of terpenoids and cannabinoids, and methods of making and using the therapeutic compositions.SOLUTION: The present invention provides a terpenoid-encapsulating PLGA nanoparticle, comprising a PLGA nanoparticle composed of copolymer poly(lactic-co-glycolic acid) and a first terpenoid encapsulated in the PLGA nanoparticle. The nanoparticle further encapsulates a second compound composed of (i) a cannabinoid or (ii) a second terpenoid other than the first terpenoid.SELECTED DRAWING: None

A composition of food or therapeutic and other substances for administration as a cloud of droplets, the cloud comprising readily-soluble droplets having a median size range of approximately 3 microns to approximately 20 microns, or 5 microns to 10 microns, or 6 microns to 10 microns, for introduction to an animal via an ortho-nasal or retro-nasal route. Agonists or antagonists may include one or more of the following: sodium iodide, sodium chloride, magnesium chloride, capsaicin, piperine, linalool, ground cinnamon, a cannabinoid, pimento, onion, clove, thyme, ginger, menthol, or TRPV antagonists, and chocolate, Irish cream, caramel, lemon, lime, mango, raspberry, watermelon, blueberry, strawberry, mint, popcorn, meat, Resolvin D2 or nicotine. Devices for delivering compositions as an aerosol are described.